Cell therapy Archives

stem cell therapy mogrify disley heart disease

Startup Scout 22 Feb 2019

This Biotech’s Algorithm Accelerates Cell Therapy Development

Mogrify is the new kid on the block for cell therapy. Based in Cambridge, UK, it boasts technology that could speed up the development of cell therapies by predicting the best chemical recipe to transform mature adult cells into other cell types. Mission: To use next-generation sequencing and gene expression data to develop more cost-effective […]

February 22, 2019 - 3 minutesmins - By Jonathan Smith

Best in Biotech 24 Dec 2018

Looking Back on 2018: Our 10 Most Popular Interviews

As 2018 draws to a close and our thoughts are torn between holiday plans and what the new year may bring, we decided to look back and revisit the people and the stories that attracted our readers the most during the year. These were well received the first time around, so we thought you might […]

December 24, 2018 - 8 minutesmins - By Helen Albert

News and Trends 17 Dec 2018

Series B Boosts British Biotech’s Cell Therapy Automation With €22.6M

The UK company Synthace has raised €22.6M to develop its software platform to automate and improve the manufacturing process in gene and cell therapy. The round, led by Hong Kong-based investor Horizons Ventures, will help to fund the development of Synthace’s software designed to automate key protocols in the lab. Furthermore, the funding will help […]

December 17, 2018 - 2 minutesmins - By Jonathan Smith

Interview 5 Dec 2018

How Automation Will Enable the Age of Cell Therapy

Scientists in biotech and pharma spend more and more of their valuable time culturing cells manually. Automated cell culture is still not standard in the early research stages, and many believe that needs to change. Philip talked to Ali Afshar, co-founder of Cytera Cellworks to discuss how the main obstacles to bringing automation to cell […]

December 5, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

bone therapeutics bone disease hip header

News and Trends 7 Nov 2018

Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease

Bone Therapeutics is going to discontinue its cell therapy Phase III trial after finding little hope of success for patients with the bone disease osteonecrosis. If all had gone as planned, the full trial would have monitored 118 patients over 24 months. However, an interim analysis on 44 patients after 12 months found little evidence […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

$bone Therapeutics cell therapy bone fracture$

News and Trends 14 Sep 2018

Cell Therapy Helps Regenerate Difficult Bone Fractures

All patients in a clinical trial run by the Belgian company Bone Therapeutics have seen an improvement in the healing of bone fractures that have had problems healing. Six months after receiving a single dose of the cell therapy developed by Bone Therapeutics, all 21 patients in the Phase I/IIa clinical trial met the primary […]

September 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Helen Tayton Martin Adaptimmune interview

Interview 11 Sep 2018

How To Break Into The Crowded Immuno-Oncology Space

The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […]

September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

pluristem cell therapy peripheral artery disease

News and Trends 13 Jun 2018

Placenta Cell Therapy Improves Mobility in Patients with Peripheral Artery Disease

The Israeli biotech Pluristem has Phase II data indicating that its cell therapy made of placenta cells can help patients suffering from peripheral artery disease recover their mobility. The trial, run in the US, Germany, South Korea and Israel, enrolled 172 patients with intermittent claudication, an early stage of peripheral artery disease where the legs […]

June 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jun 2018

People with Innate Resistance to HIV Could Provide a Functional HIV Cure

In the process of studying HIV-infected patients who naturally don’t need therapy to control the virus, scientists have found what could become a functional cure for HIV infections. A team of researchers from France, Italy, the UK and Australia has identified a molecule that could be transferred to HIV-positive people to help […]

June 8, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 May 2018

Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race

Update (23/05/2018): Investors have fully subscribed Celyad’s global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of its CAR-T technology. 18/05/2018 Celyad has raised €40M ($47M) in a global offering, which could help the company keep up with large competitors amidst recent large […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 14 May 2018

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and bluebird bio partnered to develop T cell receptor-modified T cells (TCR-Ts) as candidates for cancer immunotherapy treatments. Medigene was offered up to $250M per each of […]

May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 May 2018

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation of safer CAR-T therapies against multiple types of tumors as well as viral infections such as HIV. The Scottish biotech TC Biopharm will be working with its new partner Scotia Biologics on the development of CAR-T therapy candidates against neuroblastoma, […]

May 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cell therapy

This Biotech’s Algorithm Accelerates Cell Therapy Development

Looking Back on 2018: Our 10 Most Popular Interviews

Series B Boosts British Biotech’s Cell Therapy Automation With €22.6M

How Automation Will Enable the Age of Cell Therapy

Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease

Cell Therapy Helps Regenerate Difficult Bone Fractures

How To Break Into The Crowded Immuno-Oncology Space

Placenta Cell Therapy Improves Mobility in Patients with Peripheral Artery Disease

People with Innate Resistance to HIV Could Provide a Functional HIV Cure

Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!